Bayer Trial Win Matters More than it Seems

Dow Jones
10/30

1207 GMT - Bayer's win in a Missouri trial over the company's Roundup weedkiller is more meaningful than it might seem, given that it represents the first courtroom test of plaintiffs' alternative routes after a June ruling from the U.S. Supreme Court, analysts at Jefferies write in a note to clients. "While one verdict should not be over-extrapolated, we think it provides a positive first datapoint on plaintiffs' remaining litigation routes," the analysts say. The Supreme Court ruling pre-empted failure-to-warn claims, historically a key argument in Roundup litigation, they add. In the latest trial, the jury sided with Bayer's Monsanto on design defect, fraud and negligence claims and rejected them unanimously after a deliberation of just two hours, Jefferies says. Shares rise 3.6%.

 

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10